Brought to you by:
Large administrative databases enter crosshairs as comparative analysis shows percutaneous mechanical thrombectomy as superior to CDT for acute PE
The pitfalls of large administrative databases came to the fore during the presentation of a propensity-match scoring analysis demonstrating that percutaneous mechanical thrombectomy (MT) was superior to catheter-directed thrombolysis (CDT) in patients diagnosed with acute pulmonary embolism (PE). Junji Taukagoshi,…
The pulmonary arterial tree—it is time we branch out
Nicolas Mouawad, MD, chief of vascular surgery at McLaren Health System in Bay City, Michigan, urges vascular surgeons to “get out of their comfort zone” and become more involved in pulmonary embolism (PE) care. With more than 1 million cases…
Six-month outcomes from phase-one trial of anti-inflammatory drug to assess benefit in acute DVT patients demonstrate ‘promise’
The open-label phase of the DEXTERITY-AFP trial investigating the Bullfrog microinfusion device—which involves the perivenous injection of the anti-inflammatory drug dexamethasone to improve patency and post-thrombotic syndrome (PTS) six months after thrombus removal in symptomatic deep vein thrombosis (DVT) patients—has…
One-year CLOUT data demonstrate low rate of PTS following treatment with ClotTriever
David Dexter (Sentara Vascular Specialists, Norfolk, USA) shared one-year data from the CLOUT registry this week at The VEINS 2023 (28–30 October, Las Vegas, USA). Long-term, prospective outcome data after mechanical thrombectomy for deep vein thrombosis (DVT) are lacking. The…
VAM 2023: Learn at lunchtime
The Society for Vascular Surgery has added four lunchtime learning sessions to the VAM opening day. Topics are both clinical and non-clinical, ranging from planning for retirement, embolization tips and tricks, new deep vein thrombosis treatments and a session on…
JETi registry provides “remarkable results” for peripheral thrombectomy system
Presenting “remarkable results” from the JETi registry—a prospective, multicenter, observational study which collected real-world data on the safety, performance and clinical benefits of the JETi peripheral thrombectomy system—speaker Mahmood K. Razavi, MD, relayed the positive outcomes seen with the “powerful”…
Primary patency after venous stenting best in NIVL patients, study finds
A recent study concludes that non-thrombotic iliac vein lesion (NIVL) patients have better primary patency after venous stenting than patients with venous thrombotic disorders. Olivier Espitia (CHU de Nantes, Nantes, France) and colleagues report this main finding from a multicenter…
The top 10 most popular Vascular Specialist stories of March 2023
In March 2023, the Vascular Specialist stories grabbing readers’ attention were a response to a February letter addressing vascular surgeons’ use of social media; an interview with an advocate for more carefully considered use of venous stents; the publication of the…
ABCs for the treatment of lower-extremity acute DVTs
Ashish Gupta, MD, outlines his ABCs for confronting and treating patients with acute deep vein thrombosis (DVT) of the lower extremity, and how he developed his dictums. A is for “anticoagulation” for not more than six months of duration. Rationale:…
Venous stenting: ‘We need to evaluate use, appropriateness and clinical indication’
An analysis of venous stent usage trends in the United States from 2014 through 2021 showed a “significant increase” in stents per day placed over time, despite high-profile recalls of two dedicated venous stents from the market. Those were among…